Avexitide for Treatment of Post-Bariatric Hypoglycemia
Trial details
- Registry ID
- NCT06747468
- Drugs studied
- Avexitide
TrialRedline tracks 8 clinical trials sponsored by Amylyx Pharmaceuticals Inc.: 3 Phase 3, 1 Phase 2 / 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Avexitide for Treatment of Post-Bariatric HypoglycemiaNCT06747468 | Avexitide | Active not recruiting | 2026-07-08Actual |
| Extension Study Evaluating The Safety And Tolerability of AMX0035NCT05619783 | AMX0035 | Completed | 2024-10-16Actual |
| Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentNCT05021536 | AMX0035 | Unknown | 2024-01-19Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| AMX0035 and Progressive Supranuclear PalsyNCT06122662 | AMX0035 | Completed | 2025-09-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| AMX0035 in Adult Patients With Wolfram SyndromeNCT05676034 | AMX0035 | Active not recruiting | 2024-07-23Actual |
| Open Label Extension Study of AMX0035 in Patients With ALSNCT03488524 | AMX0035 | Completed | 2021-03-01Actual |
| Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseaseNCT03533257 | AMX0035 | Completed | 2020-10-22Actual |
| AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03127514 | AMX0035 | Completed | 2019-09-25Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-09Month | AMX0035Amylyx Pharmaceuticals Inc. · AMLX | Company-disclosed PDUFA goal dateAnnounced review target | treatment of ALS | Open original sourceRead source excerptthe FDA originally set the PDUFA date for AMX0035 for the treatment of ALS, for June 29, 2022, and then extended the review timeline for our NDA to September 2022 First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026 |
Names as written in the registry records.
NCT06747468 · Amylyx Pharmaceuticals Inc.
Before: Estimated. After: Actual.
Before: Mar 2026. After: 8 Jul 2026.
NCT06122662 · Amylyx Pharmaceuticals Inc.
Before: Estimated. After: Actual.
Before: 110 participants (planned). After: 139 participants (actual).
Before: Estimated. After: Actual.
Before: 1 Apr 2026. After: 30 Sep 2025.
Before: Active not recruiting. After: Completed.
NCT05676034 · Amylyx Pharmaceuticals Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 144 weeks in adult participants with Wolfram syndrome. After: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndrome.
NCT06747468 · Amylyx Pharmaceuticals Inc.
Before: Recruiting. After: Active not recruiting.